These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32190802)

  • 1. Basal Plasma Aldosterone Concentration Predicts Therapeutic Outcomes in Primary Aldosteronism.
    Saiki A; Otsuki M; Mukai K; Hayashi R; Shimomura I; Kurihara I; Ichijo T; Takeda Y; Katabami T; Tsuiki M; Wada N; Ogawa Y; Kawashima J; Sone M; Inagaki N; Yoshimoto T; Okamoto R; Takahashi K; Kobayashi H; Tamura K; Kamemura K; Yamamoto K; Izawa S; Kakutani M; Yamada M; Tanabe A; Naruse M
    J Endocr Soc; 2020 Apr; 4(4):bvaa011. PubMed ID: 32190802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism.
    Katabami T; Fukuda H; Tsukiyama H; Tanaka Y; Takeda Y; Kurihara I; Ito H; Tsuiki M; Ichijo T; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Sone M; Inagaki N; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Yanase T; Suzuki T; Naruse M;
    J Hypertens; 2019 Jul; 37(7):1513-1520. PubMed ID: 31145370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism.
    Murata M; Kitamura T; Tamada D; Mukai K; Kurebayashi S; Yamamoto T; Hashimoto K; Hayashi RD; Kouhara H; Takeiri S; Kajimoto Y; Nakao M; Hamasaki T; Otsuki M; Shimomura I
    J Hypertens; 2017 May; 35(5):1079-1085. PubMed ID: 28129245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical Evaluation by Confirmatory Tests after Unilateral Adrenalectomy for Primary Aldosteronism.
    Murasawa S; Kageyama K; Usutani M; Asari Y; Kinoshita N; Nakada Y; Watanuki Y; Takayasu S; Daimon M
    J Renin Angiotensin Aldosterone Syst; 2023; 2023():5732812. PubMed ID: 37265473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenal Vein Sampling Without Discontinuation of Mineralocorticoid Receptor Antagonist Therapy.
    Ganesh M; Abadin SS; Fogelfeld L
    Endocr Pract; 2020 Sep; 26(9):953-959. PubMed ID: 33471699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism.
    Nanba AT; Wannachalee T; Shields JJ; Byrd JB; Rainey WE; Auchus RJ; Turcu AF
    J Clin Endocrinol Metab; 2019 Feb; 104(2):487-492. PubMed ID: 30239792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease.
    Nakano Y; Murakami M; Hara K; Fukuda T; Horino M; Takeuchi A; Niitsu Y; Shiba K; Tsujimoto K; Komiya C; Yokoyama M; Ikeda K; Yoshimoto T; Fujii Y; Yamada T
    Clin Endocrinol (Oxf); 2023 Mar; 98(3):323-331. PubMed ID: 36367014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Aldosterone After Seated Saline Infusion Test Outperforms Captopril Test at Predicting Clinical Outcomes After Adrenalectomy for Primary Aldosteronism.
    Wu CH; Wu V; Yang YW; Lin YH; Yang SY; Lin PC; Chang CC; Tsai YC; Wang SM;
    Am J Hypertens; 2019 Oct; 32(11):1066-1074. PubMed ID: 31216359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of peripheral plasma aldosterone concentration and response to ACTH during simultaneous bilateral adrenal veins sampling to predict the source of aldosterone secretion in primary aldosteronism.
    St-Jean M; Bourdeau I; Therasse É; Lacroix A
    Clin Endocrinol (Oxf); 2020 Mar; 92(3):187-195. PubMed ID: 31867770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism.
    Lin YF; Peng KY; Chang CH; Hu YH; Wu VC; Chung SD;
    Endocrinol Metab (Seoul); 2020 Dec; 35(4):838-846. PubMed ID: 33261310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of reduced mineralocorticoid receptor activation by unilateral adrenalectomy vs mineralocorticoid antagonist treatment in patients with primary aldosteronism - Implications for depression and anxiety.
    Murck H; Adolf C; Schneider A; Schlageter L; Heinrich D; Ritzel K; Sturm L; Quinkler M; Beuschlein F; Reincke M; Künzel H
    J Psychiatr Res; 2021 May; 137():376-382. PubMed ID: 33761426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenal Ablation Versus Mineralocorticoid Receptor Antagonism for the Treatment of Primary Aldosteronism: A Single-Center Prospective Cohort Study.
    Zhou Y; Liu Q; Wang X; Wan J; Liu S; Luo T; He P; Hou J; Pu J; Wang D; Liang D; Yang Y; Wang P
    Am J Hypertens; 2022 Dec; 35(12):1014-1023. PubMed ID: 36205513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone.
    Künzel HE; Apostolopoulou K; Pallauf A; Gerum S; Merkle K; Schulz S; Fischer E; Brand V; Bidlingmaier M; Endres S; Beuschlein F; Reincke M
    J Psychiatr Res; 2012 Dec; 46(12):1650-4. PubMed ID: 23017810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial.
    Dekkers T; Prejbisz A; Kool LJS; Groenewoud HJMM; Velema M; Spiering W; Kołodziejczyk-Kruk S; Arntz M; Kądziela J; Langenhuijsen JF; Kerstens MN; van den Meiracker AH; van den Born BJ; Sweep FCGJ; Hermus ARMM; Januszewicz A; Ligthart-Naber AF; Makai P; van der Wilt GJ; Lenders JWM; Deinum J;
    Lancet Diabetes Endocrinol; 2016 Sep; 4(9):739-746. PubMed ID: 27325147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient screening of patients with aldosterone-producing adenoma using the ACTH stimulation test.
    Kita T; Furukoji E; Sakae T; Kitamura K
    Hypertens Res; 2019 Jun; 42(6):801-806. PubMed ID: 30622316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment.
    Velema M; Dekkers T; Hermus A; Timmers H; Lenders J; Groenewoud H; Schultze Kool L; Langenhuijsen J; Prejbisz A; van der Wilt GJ; Deinum J;
    J Clin Endocrinol Metab; 2018 Jan; 103(1):16-24. PubMed ID: 29099925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor antagonist treatment improved arterial stiffness in patients with primary aldosteronism: a cohort study compared with adrenalectomy.
    Liao CW; Lin YT; Tsai CH; Chang YY; Chen ZW; Lu CC; Pan CT; Chang CC; Lee BC; Chiu YW; Huang WC; Huang KH; Lai TS; Hung CS; Wu VC; Wu XM; Lin YH;
    Ther Adv Chronic Dis; 2023; 14():20406223221143233. PubMed ID: 36687666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?
    Sechi LA; Colussi GL; Novello M; Uzzau A; Catena C
    Horm Metab Res; 2015 Dec; 47(13):1000-6. PubMed ID: 26667803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary aldosteronism: renaissance of a syndrome.
    Young WF
    Clin Endocrinol (Oxf); 2007 May; 66(5):607-18. PubMed ID: 17492946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
    Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.